Shifting strategies of MNCs amidst the ascendance of Indian pharma

29 February 2024

The tides are shifting. As multinational entities such as Novartis (NOVN: VX), AstraZeneca (LSE: AZN) and Sanofi (Euronext: SAN) recalibrate their strategies in India, spurred by intensified local competition and patent expiries, domestic pharma players like Cipla, Torrent Pharma, Eris Lifesciences, and JB Chemicals are asserting their prominence.

These Indian firms are not only fortifying their market presence but are also spearheading innovative product launches and diversifying into novel therapeutic domains, reports The Pharma Letter’s India correspondent.

Novartis recently announced a comprehensive evaluation of its India operations, including its substantial stake in the listed entity Novartis India Limited (BOM: 500672). Similarly, AstraZeneca Pharma India (BOM: 506820) unveiled plans to divest its Bengaluru manufacturing facility, seeking a buyer capable of assuming operations seamlessly, potentially functioning as a Contract Manufacturing Organization.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK